Avidity Partners Management’s AN2 Therapeutics ANTX Stock Holding History

Avidity Partners Management’s Portfolio ANTX Stock Details ANTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-1,150,000	Closed	-$3.74M	–	88
2024 Q1	$3.74M	Buy	1,150,000 +10,000	+0.9%	+$109K	0.12%	81
2023 Q4	$23.4M	Buy	1,140,000 +50,600	+5%	+$847K	0.85%	46
2023 Q3	$17.5M	Buy	1,089,400 +432,200	+66%	+$4.89M	0.71%	54
2023 Q2	$5.59M	Sell	657,200 -66,000	-9%	-$475K	0.2%	79
2023 Q1	$7.14M	Sell	723,200 -20,400	-3%	-$227K	0.24%	69
2022 Q4	$7.09M	Buy	743,600 +970	+0.1%	+$13K	0.15%	64
2022 Q3	$12.9M	Buy	742,630 +54,300	+8%	+$633K	0.26%	64
2022 Q2	$5.33M	Hold	688,330	–	–	0.12%	57
2022 Q1	$10.4M	Buy	+688,330	New	+$10.4M	0.22%	63

Other funds holding ANTX

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Avidity Partners Management's ANTX Position: Q2 2024 in Review

Avidity Partners Management sold out of AN2 Therapeutics (ANTX) in Q2 2024, closing a stake of 1,150,000 shares — an estimated $3.74M sold.

Avidity Partners Management first reported a position in ANTX in Q1 2022 and held it in 9 quarters. The position peaked at $23.4M in Q4 2023. 45 funds tracked by Wall St. Rank hold ANTX as of Q2 2024.

Avidity Partners Management reported no remaining AN2 Therapeutics position as of Q2 2024 after selling out during the quarter.
Avidity Partners Management sold 1,150,000 AN2 Therapeutics shares in Q2 2024, an estimated $3.74M.
Avidity Partners Management first reported a position in AN2 Therapeutics in Q1 2022 and held it in 9 quarters.
Avidity Partners Management's AN2 Therapeutics position peaked at $23.4M in Q4 2023.
45 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q2 2024.

Based on Avidity Partners Management's 13F filing for Q2 2024, filed 14 Aug 2024.